Fibrilación auricular de inicio reciente

Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2024 Jan 2;149(1):e1-156.Texto completo  Resumen

Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021 Feb 1;42(5):373-498.Texto completo

1. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2024 Jan 2;149(1):e1-156.Texto completo  Resumen

2. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021 Feb 1;42(5):373-498.Texto completo

3. Lévy S, Steinbeck G, Santini L, et al. Management of atrial fibrillation: two decades of progress - a scientific statement from the European Cardiac Arrhythmia Society. J Interv Card Electrophysiol. 2022 Apr 13 [Epub ahead of print]. Resumen

4. Wang L, Ze F, Li J, et al. Trends of global burden of atrial fibrillation/flutter from Global Burden of Disease Study 2017. Heart. 2021 Jun;107(11):881-7.Texto completo  Resumen

5. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study. Circulation. 2014 Feb 25;129(8):837-47.Texto completo  Resumen

6. Sudlow M, Thomson R, Thwaites B, et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet. 1998 Oct 10;352(9135):1167-71. Resumen

7. Lip GY, Golding DJ, Nazir M, et al. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract. 1997 May;47(418):285-9.Texto completo  Resumen

8. Adderley NJ, Ryan R, Nirantharakumar K, et al. Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016. Heart. 2019 Jan;105(1):27-33. Resumen

9. Lip GY, Tean KN, Dunn FG. Treatment of atrial fibrillation in a district general hospital. Br Heart J. 1994 Jan;71(1):92-5.Texto completo  Resumen

10. Zarifis J, Beevers G, Lip GY. Acute admissions with atrial fibrillation in a British multiracial hospital population. Br J Clin Pract. 1997 Mar;51(2):91-6. Resumen

11. National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management. Jun 2021 [internet publication].Texto completo

12. Lip GYH, Apostolakis S. Atrial fibrillation (acute onset). BMJ Clin Evid. 2014 Nov 27;2014.Texto completo  Resumen

13. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke, results from a population-based study. Stroke. 2005 Jun;36(6):1115-9.Texto completo  Resumen

14. Paciaroni M, Agnelli G, Caso V, et al. Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. J Thromb Haemost. 2005 Jun;3(6):1218-23.Texto completo  Resumen

15. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014 Jun 26;370(26):2467-77.Texto completo  Resumen

16. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014 Jun 26;370(26):2478-86.Texto completo  Resumen

17. Katsanos AH, Kamel H, Healey JS, et al. Stroke prevention in atrial fibrillation: looking forward. Circulation. 2020 Dec 15;142(24):2371-88.Texto completo  Resumen

18. Wong CK, White HD, Wilcox RG, et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J. 2000 Dec;140(6):878-85. Resumen

19. Asanin M, Perunicic J, Mrdovic I, et al. Prognostic significance of new atrial fibrillation and its relation to heart failure following acute myocardial infarction. Eur J Heart Fail. 2005 Jun;7(4):671-6.Texto completo  Resumen

20. Mentz RJ, Chung MJ, Gheorghiade M, et al. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. Am Heart J. 2012 Dec;164(6):884-92;e2. Resumen

21. Gorenek B, Halvorsen S, Kudaiberdieva G, et al. Atrial fibrillation in acute heart failure: A position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. Eur Heart J Acute Cardiovasc Care. 2020 Jun;9(4):348-57.Texto completo  Resumen

22. He J, Yang Y, Zhang G, et al. Clinical risk factors for new-onset atrial fibrillation in acute myocardial infarction: A systematic review and meta-analysis. Medicine (Baltimore). 2019 Jun;98(26):e15960.Texto completo  Resumen

23. Falk RH. Atrial fibrillation. N Engl J Med. 2001 Apr 5;344(14):1067-78. Resumen

24. Bedford JP, Harford M, Petrinic T, et al. Risk factors for new-onset atrial fibrillation on the general adult ICU: A systematic review. J Crit Care. 2019 Oct;53:169-75.Texto completo  Resumen

25. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994 Mar 16;271(11):840-4. Resumen

26. Noubiap JJ, Nyaga UF. A review of the epidemiology of atrial fibrillation in sub-Saharan Africa. J Cardiovasc Electrophysiol. 2019 Dec;30(12):3006-16. Resumen

27. Mehra R, Chung MK, Olshansky B, et al. Sleep-disordered breathing and cardiac arrhythmias in adults: Mechanistic insights and clinical implications: A scientific statement from the American Heart Association. Circulation. 2022 Aug 1 [Epub ahead of print]. Resumen

28. Mukamal KJ, Tolstrup JS, Friberg J, et al. Alcohol consumption and risk of atrial fibrillation in men and women. Circulation. 2005 Sep 20;112(12):1736-42.Texto completo  Resumen

29. Csengeri D, Sprünker NA, Di Castelnuovo A, et al. Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes. Eur Heart J. 2021 Mar 21;42(12):1170-7.Texto completo  Resumen

30. Lee SR, Choi EK, Jung JH, et al. Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study. Eur Heart J. 2021 Dec 7;42(46):4759-68.Texto completo  Resumen

31. Agarwal A, York M, Kantharia BK, et al. Atrial fibrillation: modern concepts and management. Annu Rev Med. 2005;56:475-94. Resumen

32. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998 Sep 3;339(10):659-66.Texto completo  Resumen

33. Peters NS, Schilling RJ, Kanagaratnam P, et al. Atrial fibrillation: strategies to control, combat, and cure. Lancet. 2002 Feb 16;359(9306):593-603. Resumen

34. Iwasaki YK, Nishida K, Kato T, et al. Atrial fibrillation pathophysiology: implications for management. Circulation. 2011 Nov 15;124(20):2264-74.Texto completo  Resumen

35. Wijesurendra RS, Casadei B. Mechanisms of atrial fibrillation. Heart. 2019 Dec;105(24):1860-7. Resumen

36. Kochiadakis GE, Skalidis EI, Kalebubas MD, et al. Effect of acute atrial fibrillation on phasic coronary blood flow pattern and flow reserve in humans. Eur Heart J. 2002 May;23(9):734-41. Resumen

37. Ding WY, Gupta D, Lip GYH. Atrial fibrillation and the prothrombotic state: revisiting Virchow's triad in 2020. Heart. 2020 Oct;106(19):1463-8. Resumen

38. Prasitlumkum N, Kewcharoen J, Angsubhakorn N, et al. Orthostatic hypotension is associated with new-onset atrial fibrillation: Systemic review and meta-analysis. Indian Heart J. 2019 Jul - Aug;71(4):320-7.Texto completo  Resumen

39. Aune D, Feng T, Schlesinger S, et al. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: A systematic review and meta-analysis of cohort studies. J Diabetes Complications. 2018 May;32(5):501-11. Resumen

40. Patoulias D, Toumpourleka M, Papadopoulos C, et al. Meta-analysis evaluating the risk of atrial fibrillation with newer antidiabetics across the cardiovascular and renal outcome trials. Am J Cardiol. 2021 Jan 15;139:139-41. Resumen

41. Ziff OJ, Carter PR, McGowan J, et al. The interplay between atrial fibrillation and heart failure on long-term mortality and length of stay: Insights from the, United Kingdom ACALM registry. Int J Cardiol. 2018 Feb 1;252:117-21. Resumen

42. Reddy YNV, Carter RE, Obokata M, et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018 Aug 28;138(9):861-70.Texto completo  Resumen

43. Borlaug BA, Sharma K, Shah SJ, et al. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol. 2023 May 9;81(18):1810-34.Texto completo  Resumen

44. Noubiap JJ, Bigna JJ, Agbor VN, et al. Meta-analysis of atrial fibrillation in patients with various cardiomyopathies. Am J Cardiol. 2019 Jul 15;124(2):262-9. Resumen

45. Luo J, Li H, Qin X, et al. Increased risk of ischemic stroke associated with new-onset atrial fibrillation complicating acute coronary syndrome: A systematic review and meta-analysis. Int J Cardiol. 2018 Aug 15;265:125-31. Resumen

46. Prasitlumkum N, Rattanawong P, Limpruttidham N, et al. Frequent premature atrial complexes as a predictor of atrial fibrillation: Systematic review and meta-analysis. J Electrocardiol. 2018 Sep - Oct;51(5):760-7. Resumen

47. Xiao FP, Chen MY, Wang L, et al. Outcomes of new-onset atrial fibrillation in patients with sepsis: A systematic review and meta-analysis of 225,841 patients. Am J Emerg Med. 2021 Apr;42:23-30. Resumen

48. Chyou JY, Barkoudah E, Dukes JW, et al. Atrial fibrillation occurring during acute hospitalization: a scientific statement from the American Heart Association. Circulation. 2023 Apr 11;147(15):e676-98.Texto completo  Resumen

49. Kanjanahattakij N, Rattanawong P, Krishnamoorthy P, et al. New-onset atrial fibrillation is associated with increased mortality in critically ill patients: a systematic review and meta-analysis. Acta Cardiol. 2019 Apr;74(2):162-9. Resumen

50. Bosch NA, Cohen DM, Walkey AJ. Risk factors for new-onset atrial fibrillation in patients with sepsis: A systematic review and meta-analysis. Crit Care Med. 2019 Feb;47(2):280-7. Resumen

51. Kalra R, Patel N, Doshi R, et al. Evaluation of the incidence of new-onset atrial fibrillation after aortic valve replacement. JAMA Intern Med. 2019 Jun 3; 179(8):1122-30.Texto completo  Resumen

52. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: A scientific statement from the American Heart Association. Circulation. 2021 May 25;143(21):e984-1010.Texto completo  Resumen

53. Liu X, Wang W, Tan Z, et al. The relationship between vitamin D and risk of atrial fibrillation: a dose-response analysis of observational studies. Nutr J. 2019 Nov 14;18(1):73.Texto completo  Resumen

54. Asad Z, Abbas M, Javed I, et al. Obesity is associated with incident atrial fibrillation independent of gender: A meta-analysis. J Cardiovasc Electrophysiol. 2018 May;29(5):725-32. Resumen

55. Jones NR, Taylor KS, Taylor CJ, et al. Weight change and the risk of incident atrial fibrillation: a systematic review and meta-analysis. Heart. 2019 Dec;105(23):1799-1805.Texto completo  Resumen

56. Mujović N, Marinković M, Mihajlović M, et al. Risk factor modification for the primary and secondary prevention of atrial fibrillation. Part 2. Kardiol Pol. 2020 Mar 25;78(3):192-202. Resumen

57. Lip GY, Beevers DG, Singh SP, et al. ABC of atrial fibrillation. Aetiology, pathophysiology, and clinical features. BMJ. 1995 Nov 25;311(7017):1425-8.Texto completo  Resumen

58. Romiti GF, Corica B, Pipitone E, et al. Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients. Eur Heart J. 2021 Sep 14;42(35):3541-54.Texto completo  Resumen

59. Biddinger KJ, Emdin CA, Haas ME, et al. Association of habitual alcohol intake with risk of cardiovascular disease. JAMA Netw Open. 2022 Mar 1;5(3):e223849.Texto completo  Resumen

60. Wang Q, Guo Y, Wu C, et al. Smoking as a risk factor for the occurrence of atrial fibrillation in men versus women: a meta-analysis of prospective cohort studies. Heart Lung Circ. 2018 Jan;27(1):58-65. Resumen

61. Aune D, Schlesinger S, Norat T, et al. Tobacco smoking and the risk of atrial fibrillation: A systematic review and meta-analysis of prospective studies. Eur J Prev Cardiol. 2018 Sep;25(13):1437-51.Texto completo  Resumen

62. Upala S, Shahnawaz A, Sanguankeo A. Psoriasis increases risk of new-onset atrial fibrillation: a systematic review and meta-analysis of prospective observational studies. J Dermatolog Treat. 2017 Aug;28(5):406-10. Resumen

63. Ungprasert P, Srivali N, Kittanamongkolchai W. Risk of incident atrial fibrillation in patients with rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis. 2017 Apr;20(4):434-41. Resumen

64. Elliott AD, Linz D, Mishima R, et al. Association between physical activity and risk of incident arrhythmias in 402 406 individuals: evidence from the UK Biobank cohort. Eur Heart J. 2020 Apr 14;41(15):1479-86.Texto completo  Resumen

65. Chung MK, Eckhardt LL, Chen LY, et al. Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American Heart Association. Circulation. 2020 Apr 21;141(16):e750-72.Texto completo  Resumen

66. Ricci C, Gervasi F, Gaeta M, et al. Physical activity volume in relation to risk of atrial fibrillation: a non-linear meta-regression analysis. Eur J Prev Cardiol. 2018 May;25(8):857-66.Texto completo  Resumen

67. Xue Z, Zhou Y, Wu C, et al. Dose-response relationship of cardiorespiratory fitness with incident atrial fibrillation. Heart Fail Rev. 2020 May;25(3):419-25. Resumen

68. Baum BJ, Roberts MW, Brahim JS, et al. The National Institute of Dental Research Clinical Dental Staff Fellowship. J Dent Educ. 1988 Sep;52(9):535-6. Resumen

69. Levin MG, Judy R, Gill D, et al. Genetics of height and risk of atrial fibrillation: A Mendelian randomization study. PLoS Med. 2020 Oct;17(10):e1003288.Texto completo  Resumen

70. Marott JL, Skielboe AK, Dixen U, et al. Increasing population height and risk of incident atrial fibrillation: the Copenhagen City Heart Study. Eur Heart J. 2018 Dec 1;39(45):4012-4019.Texto completo  Resumen

71. Delluc A, Wang TF, Yap ES, et al. Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH. J Thromb Haemost. 2019 Aug;17(8):1247-52.Texto completo  Resumen

72. Erichsen R, Christiansen CF, Mehnert F, et al. Colorectal cancer and risk of atrial fibrillation and flutter: a population-based case-control study. Intern Emerg Med. 2012 Oct;7(5):431-8. Resumen

73. Tamargo J, Caballero R, Delpón E. Cancer chemotherapy and cardiac arrhythmias: a review. Drug Saf. 2015 Feb;38(2):129-52. Resumen

74. Potter AS, Hulsurkar MM, Wu L, et al. Kinase inhibitors and atrial fibrillation: mechanisms of action and clinical implications. JACC Clin Electrophysiol. 2023 Apr;9(4):591-602.Texto completo  Resumen

75. Gorenek B, Pelliccia A, Benjamin EJ, et al. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Europace. 2017 Feb 1;19(2):190-225.Texto completo  Resumen

76. Lavie CJ, Pandey A, Lau DH, et al. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. J Am Coll Cardiol. 2017 Oct 17;70(16):2022-35.Texto completo  Resumen

77. Middeldorp ME, Pathak RK, Meredith M, et al. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on atrial fibrillation: the REVERSE-AF study. Europace. 2018 Dec 1;20(12):1929-35.Texto completo  Resumen

78. Wingerter R, Steiger N, Burrows A, et al. Impact of Lifestyle Modification on Atrial Fibrillation. Am J Cardiol. 2020 Jan 15;125(2):289-97. Resumen

79. Gorenek B Chair, Bax J, Boriani G, et al. Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace. 2017 Sep 1;19(9):1556-78.Texto completo  Resumen

80. Lopez Perales CR, Van Spall HGC, Maeda S, et al. Mobile health applications for the detection of atrial fibrillation: a systematic review. Europace. 2021 Jan 27;23(1):11-28.Texto completo  Resumen

81. Guo Y, Wang H, Zhang H, et al. Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. J Am Coll Cardiol. 2019 Nov 12;74(19):2365-2375.Texto completo  Resumen

82. O'Sullivan JW, Grigg S, Crawford W, et al. Accuracy of smartphone camera applications for detecting atrial fibrillation: A systematic review and meta-analysis. JAMA Netw Open. 2020 Apr 1;3(4):e202064.Texto completo  Resumen

83. Prasitlumkum N, Cheungpasitporn W, Chokesuwattanaskul A, et al. Diagnostic accuracy of smart gadgets/wearable devices in detecting atrial fibrillation: A systematic review and meta-analysis. Arch Cardiovasc Dis. 2021 Jan;114(1):4-16.Texto completo  Resumen

84. Dörr M, Nohturfft V, Brasier N, et al. The WATCH AF Trial: SmartWATCHes for detection of atrial fibrillation. JACC Clin Electrophysiol. 2019 Feb;5(2):199-208.Texto completo  Resumen

85. Perez MV, Mahaffey KW, Hedlin H, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019 Nov 14;381(20):1909-17.Texto completo  Resumen

86. Baumgartner C, da Costa BR, Collet TH, et al; Thyroid Studies Collaboration. Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation. Circulation. 2017 Nov 28;136(22):2100-16.Texto completo  Resumen

87. Hijazi Z, Siegbahn A, Andersson U, et al; ARISTOTLE Investigators. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014 Feb 11;129(6):625-34.Texto completo  Resumen

88. Bai Y, Guo SD, Liu Y, et al. Relationship of troponin to incident atrial fibrillation occurrence, recurrence after radiofrequency ablation and prognosis: a systematic review, meta-analysis and meta-regression. Biomarkers. 2018 Sep;23(6):512-7. Resumen

89. Kotecha D, Mohamed M, Shantsila E, et al. Is echocardiography valid and reproducible in patients with atrial fibrillation? A systematic review. Europace. 2017 Sep 1;19(9):1427-38.Texto completo  Resumen

90. Schwint AE, Itoiz ME, Cabrini RL. A quantitative histochemical study of the microvasculature of irradiated skin. Cell Mol Biol. 1990;36(3):253-64. Resumen

91. Fauchier L, Clementy N, Pelade C, et al. Patients with ischemic stroke and incident atrial fibrillation: a nationwide cohort study. Stroke. 2015 Sep;46(9):2432-7.Texto completo  Resumen

92. Singer DE, Chang Y, Borowsky LH, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013 Jun 21;2(3):e000250.Texto completo  Resumen

93. Fox KAA, Lucas JE, Pieper KS, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017 Dec 21;7(12):e017157.Texto completo  Resumen

94. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13;285(22):2864-70.Texto completo  Resumen

95. Yarmohammadi H, Varr BC, Puwanant S, et al. Role of CHADS2 score in evaluation of thromboembolic risk and mortality in patients with atrial fibrillation undergoing direct current cardioversion (from the ACUTE Trial Substudy). Am J Cardiol. 2012 Jul 15;110(2):222-6. Resumen

96. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006 Mar;151(3):713-9. Resumen

97. Saliba W, Gronich N, Barnett-Griness O, et al. Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study. Am J Med. 2016 Aug;129(8):843-9.Texto completo  Resumen

98. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010 Nov;138(5):1093-100. Resumen

99. Jonas DE, Kahwati LC, Yun JDY, et al. Screening for atrial fibrillation with electrocardiography: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018 Aug 7;320(5):485-98.Texto completo  Resumen

100. Taggar JS, Coleman T, Lewis S, et al. Accuracy of methods for detecting an irregular pulse and suspected atrial fibrillation: a systematic review and meta-analysis. Eur J Prev Cardiol. 2016 Aug;23(12):1330-8.Texto completo  Resumen

101. Mahajan R, Perera T, Elliott AD, et al. Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis. Eur Heart J. 2018 Apr 21;39(16):1407-15.Texto completo  Resumen

102. US Preventive Services Task Force; Davidson KW, Barry MJ, Mangione CM, et al. Screening for atrial fibrillation: US Preventive Services Task Force recommendation statement. JAMA. 2022 Jan 25;327(4):360-7.Texto completo  Resumen

103. Petryszyn P, Niewinski P, Staniak A, et al. Effectiveness of screening for atrial fibrillation and its determinants. A meta-analysis. PLoS One. 2019;14(3):e0213198.Texto completo  Resumen

104. Gillis AM, Morck M. Atrial fibrillation after DDDR pacemaker implantation. J Cardiovasc Electrophysiol. 2002 Jun;13(6):542-7. Resumen

105. Biersteker TE, Schalij MJ, Treskes RW. Impact of mobile health devices for the detection of atrial fibrillation: Systematic review. JMIR Mhealth Uhealth. 2021 Apr 28;9(4):e26161.Texto completo  Resumen

106. Kanji S, Stewart R, Fergusson DA, et al. Treatment of new-onset atrial fibrillation in noncardiac intensive care unit patients: a systematic review of randomized controlled trials. Crit Care Med. 2008 May;36(5):1620-4. Resumen

107. Okcun B, Yigit Z, Yildiz A, et al. What should be the primary treatment in atrial fibrillation: ventricular rate control or sinus rhythm control with long-term anticoagulation? J Int Med Res. 2009 Mar-Apr;37(2):464-71. Resumen

108. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51.Texto completo  Resumen

109. Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996 Mar 15;93(6):1262-77.Texto completo  Resumen

110. Lopes RD, Rordorf R, De Ferrari GM, et al; ARISTOTLE Committees and Investigators. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018 Mar 13;71(10):1063-74.Texto completo  Resumen

111. Pope MK, Hall TS, Schirripa V, et al. Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data. BMJ. 2021 Oct 27;375:e066450.Texto completo  Resumen

112. Pluymaekers NAHA, Dudink EAMP, Luermans JGLM, et al. Early or delayed cardioversion in recent-onset atrial fibrillation. N Engl J Med. 2019 Apr 18;380(16):1499-1508.Texto completo  Resumen

113. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001 May 10;344(19):1411-20.Texto completo  Resumen

114. Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020 Oct 1;383(14):1305-16.Texto completo  Resumen

115. Alpert JS. Take-home messages from the recently updated AHA/ACC guidelines for atrial fibrillation. Am J Med. 2019 Dec;132(12):1363-4. Resumen

116. Ganesan AN, Chew DP, Hartshorne T, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J. 2016 Feb 16;37(20):1591-602.Texto completo  Resumen

117. Lilli A, Di Cori A, Zacà V. Thromboembolic risk and effect of oral anticoagulation according to atrial fibrillation patterns: a systematic review and meta-analysis. Clin Cardiol. 2017 Sep;40(9):641-7.Texto completo  Resumen

118. O'Dell KM, Igawa D, Hsin J. New oral anticoagulants for atrial fibrillation: a review of clinical trials. Clin Ther. 2012 Apr;34(4):894-901. Resumen

119. Gibson CM, Basto AN, Howard ML. Direct oral anticoagulants in cardioversion: a review of current evidence. Ann Pharmacother. 2018 Mar;52(3):277-84. Resumen

120. National Institute for Health and Care Excellence. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. Jul 2021 [internet publication].Texto completo

121. Mincu RI, Mahabadi AA, Totzeck M, et al. Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation - a meta-analysis of more than 17000 patients. Sci Rep. 2019 Feb 28;9(1):3011.Texto completo  Resumen

122. Telles-Garcia N, Dahal K, Kocherla C, et al. Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis. Int J Cardiol. 2018 Oct 1;268:143-8. Resumen

123. Bassand JP, Virdone S, Badoz M, et al. Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. Blood Adv. 2021 Feb 23;5(4):1081-91.Texto completo  Resumen

124. Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012 Aug 1;110(3):453-60. Resumen

125. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.Texto completo  Resumen

126. Halperin JL, Hankey GJ, Wojdyla DM, et al; ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014 Jul 8;130(2):138-46.Texto completo  Resumen

127. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.Texto completo  Resumen

128. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104.Texto completo  Resumen

129. Hanon O, Vidal JS, Pisica-Donose G, et al. Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. Heart. 2021 Sep;107(17):1376-82. Resumen

130. Caldeira D, Rodrigues FB, Barra M, et al. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart. 2015;101:1204-1211. Resumen

131. Lowenstern A, Al-Khatib SM, Sharan L, et al. Interventions for preventing thromboembolic events in patients with atrial fibrillation: a systematic review. Ann Intern Med. 2018 Dec 4;169(11):774-87.Texto completo  Resumen

132. Ng SS, Lai NM, Nathisuwan S, et al. Comparative efficacy and safety of warfarin care bundles and novel oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis. Sci Rep. 2020 Jan 20;10(1):662.Texto completo  Resumen

133. Sharma M, Cornelius VR, Patel JP, et al. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015 Jul 21;132(3):194-204.Texto completo  Resumen

134. Gommans E, Grouls RJE, Kerkhof D, et al. Dabigatran trough concentrations in very elderly patients. Eur J Hosp Pharm. 2021 Jul;28(4):231-3.Texto completo  Resumen

135. Del-Carpio Munoz F, Gharacholou SM, Munger TM, et al. Meta-analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation. Am J Cardiol. 2016 Jan 1;117(1):69-75. Resumen

136. Jin H, Zhu K, Wang L, et al. A network meta-analysis of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and diabetes mellitus. Acta Cardiol. 2021 Nov;76(9):960-9. Resumen

137. Huang HK, Liu PP, Lin SM, et al. Diabetes-related complications and mortality in patients with atrial fibrillation receiving different oral anticoagulants: a nationwide analysis. Ann Intern Med. 2022 Apr;175(4):490-8. Resumen

138. Gallego P, Roldán V, Marin F, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med. 2014 Nov;127(11):1083-8.Texto completo  Resumen

139. Lip GY, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest. 2014 Sep;146(3):719-26. Resumen

140. Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. Europace. 2020 Feb 1;22(2):184.Texto completo

141. Heldal M, Atar D. Pharmacological conversion of recent-onset atrial fibrillation: a systematic review. Scand Cardiovasc J Suppl. 2013 Feb;47(1):2-10. Resumen

142. Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007 Sep 6;357(10):987-99.Texto completo  Resumen

143. Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):597-605. Resumen

144. Hohnloser SH, Crijns HJ, van Eickels M, et al; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009 Feb 12;360(7):668-78.Texto completo  Resumen

145. Roy D, Pratt CM, Torp-Pedersen C, et al; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008 Mar 25;117(12):1518-25.Texto completo  Resumen

146. Kowey PR, Dorian P, Mitchell LB, et al; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009 Dec;2(6):652-9.Texto completo  Resumen

147. Camm AJ, Capucci A, Hohnloser SH, et al; AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011 Jan 18;57(3):313-21.Texto completo  Resumen

148. National Institute for Health and Care Excellence. Dronedarone for the treatment of non-permanent atrial fibrillation. 1 December 2012 [internet publication].Texto completo

149. Kochiadakis GE, Igoumenidis NE, Hamilos ME, et al. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation. Am J Cardiol. 2007 Jun 15;99(12):1721-5.Texto completo  Resumen

150. Xanthos T, Bassiakou E, Vlachos IS, et al. Intravenous and oral administration of amiodarone for the treatment of recent onset atrial fibrillation after digoxin administration. Int J Cardiol. 2007 Oct 18;121(3):291-5. Resumen

151. Xanthos T, Prapa V, Papadimitriou D, et al. Comparative study of intravenous amiodarone and procainamide in the treatment of atrial fibrillation of recent onset. Minerva Cardioangiol. 2007 Aug;55(4):433-41. Resumen

152. Markey GC, Salter N, Ryan J. Intravenous flecainide for emergency department management of acute atrial fibrillation. J Emerg Med. 2018 Mar;54(3):320-27. Resumen

153. Torp-Pedersen C, Raev DH, Dickinson G, et al. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion. Circ Arrhythm Electrophysiol. 2011 Oct;4(5):637-43.Texto completo  Resumen

154. Sorino M, Colonna P, De Luca L, et al. Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study). J Cardiovasc Med (Hagerstown). 2007 Dec;8(12):1034-42. Resumen

155. Grönberg T, Hartikainen JE, Nuotio I, et al. Anticoagulation, CHA2DS2VASc score, and thromboembolic risk of cardioversion of acute atrial fibrillation (from the FinCV study). Am J Cardiol. 2016 Apr 15;117(8):1294-8. Resumen

156. Sulzgruber P, Wassmann S, Semb AG, et al. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. Eur Heart J Cardiovasc Pharmacother. 2019 Jul 1;5(3):171-80.Texto completo  Resumen

157. Barra S, Providência R. Anticoagulation in atrial fibrillation. Heart. 2021 Mar;107(5):419-27. Resumen

158. Apenteng PN, Virdone S, Hobbs FR, et al. Two-year outcomes of UK patients newly diagnosed with atrial fibrillation: findings from the prospective observational cohort study GARFIELD-AF. Br J Gen Pract. 2022 Feb 18 [Epub ahead of print].Texto completo  Resumen

159. Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000 Nov;49(11):1033-46. Resumen

160. Um KJ, McIntyre WF, Healey JS, et al. Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and meta-analysis. Europace. 2019 Jun 1;21(6):856-63.Texto completo  Resumen

161. Vitali F, Serenelli M, Airaksinen J, et al. CHA2DS2-VASc score predicts atrial fibrillation recurrence after cardioversion: Systematic review and individual patient pooled meta-analysis. Clin Cardiol. 2019 Mar;42(3):358-64.Texto completo  Resumen

162. Voskoboinik A, Kalman JM, De Silva A, et al. Alcohol Abstinence in Drinkers with Atrial Fibrillation. N Engl J Med. 2020 Jan 2;382(1):20-28.Texto completo  Resumen

163. Jabre P, Roger VL, Murad MH, et al. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. Circulation. 2011 Apr 19;123(15):1587-93.Texto completo  Resumen

164. Lunde ED, Nielsen PB, Riahi S, et al. Associations between socioeconomic status, atrial fibrillation, and outcomes: a systematic review. Expert Rev Cardiovasc Ther. 2018 Nov;16(11):857-73. Resumen

165. Liu X, Guo L, Xiao K, et al. The obesity paradox for outcomes in atrial fibrillation: evidence from an exposure-effect analysis of prospective studies. Obes Rev. 2020 Mar;21(3):e12970. Resumen

166. Ruddox V, Sandven I, Munkhaugen J, et al. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis. Eur J Prev Cardiol. 2017 Sep;24(14):1555-66.Texto completo  Resumen

167. Chang TY, Lip GYH, Chen SA, et al. Importance of risk reassessment in patients with atrial fibrillation in guidelines: Assessing risk as a dynamic process. Can J Cardiol. 2019 May;35(5):611-8. Resumen

168. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310:2050-2060.Texto completo  Resumen

169. Abdul-Aziz AA, Altawil M, Lyon A, et al. Lifestyle Therapy for the Management of Atrial Fibrillation. Am J Cardiol. 2018 May 1;121(9):1112-1117. Resumen

170. Yu Z, Zhang D, Ji Q, et al. Inhibition of the renin-angiotensin-aldosterone system prevents and cures atrial fibrillation: An overview of systematic reviews. Medicine (Baltimore). 2021 May 7;100(18):e25559.Texto completo  Resumen